Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project by Campsmith, Michael L et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Research
Self-reported health-related quality of life in persons with 
HIV infection: results from a multi-site interview project
Michael L Campsmith*1, Allyn K Nakashima1 and Arthur J Davidson2
Address: 1Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 
Atlanta, Georgia, USA and 2Denver Department of Public Health, Denver, Colorado, USA
Email: Michael L Campsmith* - mcampsmith@cdc.gov; Allyn K Nakashima - anakashima@cdc.gov; Arthur J Davidson - art.davidson@dhha.org
* Corresponding author    
HIV/AIDSquality of lifeantiretroviral therapy
Abstract
Background: To examine demographic and behavioral associations with self-reported health-
related quality of life (HRQOL) among persons with HIV infection or AIDS.
Methods: Analysis of interviews with persons ≥ 18 years of age reported through routine disease
surveillance with HIV infection or AIDS to nine state and local health departments from January
1995 through December 1996. Scales were constructed from validated measures of HRQOL, and
mean scores were calculated (lower scores signified poorer HRQOL). Measures of HRQOL
included Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental
Health, Energy/Fatigue, and Cognitive Functioning. Differences in HRQOL were examined by
various demographic and behavioral factors, including taking antiretroviral medication.
Results: HRQOL data were available for 3778 persons. Factors associated with lower HRQOL
scores included older age, female sex, black or Hispanic race/ethnicity, injection drug use, lower
education and income, no private health insurance, and lower CD4 count. In multivariate analysis,
lower CD4 count was the factor most consistently associated with lower HRQOL. Taking
antiretroviral medication was not associated with differences in HRQOL regardless of CD4 count.
Conclusions: Perception of HRQOL varied in a population with HIV infection or AIDS. On most
HRQOL measures, lower CD4 count was associated with lower HRQOL. Measurement of
HRQOL can assist in understanding the long-term effects of disease and treatment on persons with
HIV.
Background
New antiretroviral therapies introduced in the mid 1990s
have allowed many persons with HIV infection to live
longer before progressing to AIDS, and to have longer sur-
vival following an AIDS diagnosis [1–3]. The annual
number of deaths due to AIDS in the United States peaked
in 1995 and has since declined [4], resulting in an increase
in the number of prevalent AIDS cases. Current clinical
guidelines [5] call for persons infected with HIV to take a
combination of antiretroviral medications to decrease vi-
ral load, maintain immune cell function, and prevent the
development of resistant viral strains. Thus, for many pa-
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tients the treatment of HIV has evolved more toward a
model of chronic disease management, with patients
taking a variety of potent medications for extended peri-
ods of time.
Besides clinical outcomes, health-related quality of life
(HRQOL) and disability are important issues for persons
treated for chronic diseases [6–11], including HIV infec-
tion [12–14]. Populations with HIV infection or AIDS
have reported different levels of HRQOL, both in clinical
trials [15–18] and population-based research [19–21]. We
present summary information from a multi-site supple-
mental surveillance project that describes the levels of HR-
QOL reported by HIV-infected persons in different
demographic and behavioral risk factor groups, stressing
the relationship between disease progression and
HRQOL.
Methods
Since 1990, the Centers for Disease Control and Preven-
tion (CDC) has conducted the Supplement to HIV/AIDS
Surveillance (SHAS) Project, an ongoing cross-sectional
interview study designed to collect supplemental behavio-
ral surveillance data from persons with HIV infection [22].
Persons 18 years of age or older reported with HIV or
AIDS through routine case surveillance were eligible for
participation. Participants were enrolled using one of
three methods: (1) facility-based recruitment of all eligi-
ble persons seeking treatment at selected health care facil-
ities in Atlanta, Connecticut, Denver, Detroit, Florida, and
New Jersey; (2) population-based recruitment of all eligi-
ble persons in Arizona, Delaware, New Mexico and South
Carolina; and (3) population-based recruitment of a 30%
sample of men who have sex with men (MSM) and 100%
of all other eligible persons in Washington State and Los
Angeles County, California. During the period examined
for this analysis, Arizona, Denver, Detroit, New Jersey,
and South Carolina interviewed persons with HIV infec-
tion in addition to those with AIDS. (Three sites-Detroit,
South Carolina, and Washington-opted not to collect data
using the HRQOL module and were excluded from all
analyses.) Informed consent was obtained from all partic-
ipants prior to the interview, and the study has received
institutional review board approval at both the CDC and
local levels. Trained interviewers conducted a standard-
ized interview in either English or Spanish that includes
questions on demographic characteristics, drug and alco-
hol use, sexual behaviors, and medical and social service
information. Data are self-reported and are not verified
through medical record review or clinical tests. On aver-
age interviews take approximately 45 minutes to com-
plete. Data were sent to CDC without any personal
identifying information.
The format of the SHAS Project allows the questionnaire
to be modified to collect data on additional topics of in-
terest. From January 1995 through December 1996, a
module of questions adapted from research conducted by
Albert Wu and colleagues [23] was added to study the lev-
els of self-reported HRQOL. Wu et al compiled questions
from the RAND Medical Outcomes Study (MOS) [24] as
well as additional items to measure other dimensions of
health (energy, distress, and cognitive function) potential-
ly relevant to HIV disease. Wu et al found that their mod-
ified health status questionnaire reliably and distinctly
measured aspects of health among HIV-positive persons
recruited for two clinical trials of zidovudine. HIV-infect-
ed persons who were asymptomatic had higher scores on
most HRQOL dimensions-indicating relatively less disa-
bility and a better quality of life-than persons who were
diagnosed with early AIDS related complex.
The SHAS Quality of Life module was used to collect in-
formation on self-reported HRQOL in the following di-
mensions: Overall Health, Pain, Physical Functioning,
Role Functioning, Social Functioning, Mental Health, En-
ergy/Fatigue, and Cognitive Functioning. These eight HR-
QOL dimensions were measured using 24 questions (a
subset of the 30 MOS questions used by Wu et al). Re-
sponse scores for each HRQOL dimension were trans-
formed linearly on scale of 0 to 100. Multi-item
dimensions were scored by summing item responses, and
internal consistency coefficients (Cronbach's alpha [25])
were calculated. For each dimension, lower scores indicate
relatively lower self-perceived quality of life for that health
measure compared to higher scores.
Analysis of variance tests were used to compare crude
mean HRQOL scores across demographic and behavioral
categories; because the sample was large the significance
level for univariate analysis was set at P < 0.01. Multivari-
ate linear regression (least-squares means) was used to
identify independent factors associated with HRQOL in
the statistical models; analyses included variables noted
from the literature as potentially associated with quality
of life (e.g., age, sex, education, and income). Linear re-
gression models were then constructed using the separate
HRQOL dimension scores as the outcomes; here, the sig-
nificance level was set at P < 0.05. Tukey-Kramer adjust-
ments for multiple comparisons were used where
appropriate. Age and education were included in the
models as continuous predictor variables; CD4 count,
gender, income, race/ethnicity, mode of exposure, time
known to be HIV+, currently taking antiretroviral therapy
(yes versus no), and type of SHAS recruitment (popula-
tion-based versus facility-based) were included as categor-
ical predictor variables. To simplify comparisons across
HRQOL dimensions, we report results for models includ-
ing all predictor variables, regardless of whether any indi-Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/12
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vidual variable was predictive of the outcome. All analyses
were conducted using SAS Version 6.12 (SAS Institute,
Inc., Cary, NC, USA).
Results
From January 1995 through December 1996, 6128 per-
sons were identified for interview at the nine sites that ad-
ministered the HRQOL module. Of these, 614 were found
to have died before they could be contacted. Of the re-
maining 5514, 4246 (77.0%) completed SHAS inter-
views, 463 (8.4%) refused to participate, 394 (7.1%)
could not be located, and 353 (6.4%) were located but
were too ill (either physically or mentally) to participate.
Sites phased out the HRQOL module at various times dur-
ing the two-year period; HRQOL data were available from
3778 interviews. Persons administered the HRQOL mod-
ule were demographically similar to persons who did not
participate in SHAS (refused, could not be located, or too
ill), except that a slightly higher percentage of those who
did not participate were male (76.0% vs. 73.5%) and
white (40.5% vs. 34.0%; chi-square test of proportions, P
< 0.001).
The multi-item HRQOL dimensions of Physical Function-
ing, Role Functioning, Mental Health, Energy/Fatigue,
and Cognitive Functioning were internally consistent in
our sample (Table 1; all Cronbach's alpha ≥ 0.84).
Demographic characteristics of the HRQOL module par-
ticipants are shown in Table 2. The median age of those
providing HRQOL information was 37 years (range: 18–
84). AIDS had been diagnosed in 81.1% of participants,
70.9% had known of their HIV infection for 12 months or
more, and 65.0% were currently taking any antiretroviral
medications (i.e., zidovudine, didanosine, zalcitabine,
stavudine, or experimental HIV drugs, including protease
inhibitors). The population mean score on the dimension
of Overall Health was 50.4 (on a scale of 0 to 100).
Mean HRQOL scores were stratified across demographic
and behavioral categories and compared by using the
analysis of variance. As seen in Table 2, lower Overall
Health scores were associated with older age, female sex,
black or Hispanic race/ethnicity, HIV exposure through
injection drug use, lower CD4 count, less than 12 years of
education, no private health insurance, and lower in-
come. Mean scores for each of the remaining HRQOL di-
mensions were also computed and similarly compared by
demographic characteristics. In most instances in which
significant differences were found, lower HRQOL was as-
sociated with the factors already listed (data not
displayed).
In linear regression analyses, lower CD4 count, less edu-
cation, lower income, and older age were consistently as-
sociated with lower HRQOL scores. Table 3 shows the
HRQOL scores stratified by CD4 count adjusted for the
other predictor variables, using the Least Squares Means
technique (the group labeled "CD4 Unknown" includes
those who never had a CD4 test as well as those who had
a CD4 test but could not recall the result). On all but two
of the HRQOL measures, self-reported HRQOL decreased
as CD4 count decreased. CD4 count was not associated
with the measures of Mental Health and Cognitive
Function.
We were also interested in the relationship between
antiretroviral therapy and HRQOL. Most of the study pop-
ulation (65.0%) was currently taking antiretroviral medi-
cation. Taking antiretroviral medication differed
significantly by CD4 count: 75.1% of those with a CD4
count of <200 were currently taking antiretroviral medica-
tion, compared to 68.5% with a CD4 count of 200–499,
and 27.3% with a CD4 count of ≥ 500 (P < 0.001, Mantel
Hantzel chi-square test for trend). In univariate analysis,
current antiretroviral therapy was associated with only
two HRQOL dimensions: therapy was negatively
associated with Role Function and positively associated
with Mental Health. For the dimension of Role Function,
Table 1: Health-related quality of life measures: definitions and the consistency of multi-item measures
Measures Definition Number of Items Cronbachs's Alphaa
Overall Health Perception of current health 1 –
Pain Perception of overall pain 1 –
Physical Functioning Extent to which health interferes with a variety of activities 6 0.84
Role Functioning Extent to which health interferes with usual daily activities 2 0.89
Social Functioning Extent to which health interferes with normal social activities 1 –
Mental Health General mood or affect, including depression, anxiety, well-being 5 0.85
Energy/Fatigue Extent to which patient felt fatigued 4 0.87
Cognitive Functioning Extent to which reasoning or concentration was impaired 4 0.88
a measure of internal consistency reliability for multi-item scalesHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/12
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currently taking antiretroviral medication was associated
with a lower HRQOL score (44.3) than that of persons not
currently taking medication (49.8; P < 0.001). However,
in the multivariate models examining HRQOL scores
stratified by CD4 count, currently taking antiretroviral
medication was not associated with differences in
HRQOL.
Table 2: Overall Health score by demographic variables (N = 3778)




18–29 605 (16.0) 55.7 (ref.)
30–39 1783 (47.2) 51.4b -4.3
40–49 1055 (27.9) 47.2c -8.5
≥50 335 (8.9) 45.4c -10.3
Gender
Male 2778 (73.5) 51.3 (ref.)
Female 1000 (26.5) 47.7c -3.6
Race/ethnicity
White 1286 (34.0) 54.4 (ref.)
Black 1547 (41.0) 48.5c -5.9
Hispanic 901 (23.8) 47.8c -6.6
Other 44 (1.2) 50.5 -3.9
Mode of exposure
MSM 1481 (39.2) 56.3 (ref.)
IDU 982 (26.0) 42.1c -14.2
MSM/IDU 310 (8.2) 51.1 -5.2
Heterosexual contact 691 (18.3) 49.7c -6.6
Other (includes NIR) 314 (8.3) 49.0c -7.3
Most recent CD4 count
<200 1950 (56.4) 46.7 (ref.)
200–499 812 (23.5) 58.0c +11.3
≥500 259 (7.5) 64.9c +18.2
Unknown 433 (12.5) 48.7 +2.0
Education
<12 years 1329 (35.2) 44.7 (ref.)
≥ 12 years 2449 (64.8) 53.4c +8.7
Health insurance status
Private insurance 443 (12.7) 60.3 (ref.)
Public insurance 1889 (54.0) 47.2c -13.1
None 1167 (33.3) 52.3c -8.0
Income
<$10,000/year 2135 (61.1) 47.1 (ref.)
≥$10,000/year 1357 (38.9) 57.2c +10.1
Time HIV+ status known
<12 month 1091 (29.1) 52.1 (ref.)
≥12 months 2662 (70.9) 49.7 -2.4
Current antiretroviral therapy
Yes 2380 (65.0) 50.8 (ref.)
No 1279 (35.0) 50.1 -0.7
Type of recruitment
Facility-based 2386 (63.2) 49.5 (ref.)
Population-based 1392 (38.4) 51.8 +2.3
group totals may not sum to overall total because of missing data;
 a analysis of variance; Tukey-Kramer adjustment for multiple comparisons;
 b = P < 0.01; c = P < 0.001;
 ref. = reference group; MSM = men who have sex with men; IDU = injection drug use; MSM/IDU = men who have sex with men and injection drug 
use; NIR = no identified riskHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/12
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Discussion
Disability and health-related quality of life are becoming
increasingly important issues associated with HIV disease.
New developments in the treatment of HIV have pro-
duced dramatic improvements in the clinical and immu-
nologic health for many patients, with a resulting
reduction in deaths due to AIDS in the United States.
Along with clinical indicators of morbidity and mortality,
measures of HRQOL (such as physical functioning, men-
tal health, pain, and energy) can help guide treatment de-
cisions for both patients and providers.
Like other researchers, we found that lower HRQOL scores
and poorer perception of health were associated with
more advanced disease. A majority of the SHAS partici-
pants had an AIDS diagnosis at the time of their interview.
However, a broad range of CD4 levels is represented in the
study population. Both facility-based and population-
based strategies were used to recruit SHAS participants.
The study population included large numbers of women,
racial/ethnic minorities, and persons infected with HIV
through injection drug use or heterosexual risk. These
groups have not been extensively reported in previous
studies of HIV and HRQOL, in which the populations
have been more representative of white male clinic pa-
tients [16–18,26–28]. Where significant differences were
found by univariate analysis, women, blacks, Hispanics,
and persons infected with HIV through injection drug use
had lower mean HRQOL scores. However, in multivariate
linear regression, sex, race/ethnicity, and HIV infection
risk were not associated with differences in HRQOL when
stratified by CD4 count.
Several limitations should be considered in the interpreta-
tion of our findings. SHAS is a cross-sectional interview
study with data self-reported by the participant. Critical
indicators of disease progression, such as CD4 count, were
not confirmed through clinical testing or review of medi-
cal records. Among those who reported having ever had a
CD4 count, 12.5% could not recall the most recent CD4
count; on most HRQOL dimensions their scores lay be-
tween the scores for the lowest and middle CD4 groups.
This finding suggests they were more advanced in their
HIV disease; indeed, 83.6% were reported to the national
surveillance system as having AIDS. The SHAS question-
naire also did not adequately capture the composition of
a person's past and current antiretroviral therapies, or the
duration of, and adherence to, those therapies. Specifical-
ly, this questionnaire does not assess the effects of pro-
tease inhibitor therapy on HRQOL, as those medications
were introduced during the period the HRQOL module
was used. Of the 2380 persons taking antiretroviral medi-
cations at the time of interview, only 39 (1.6%) reported
taking protease inhibitors. Although other studies have
also reported that questions adapted from the MOS dis-
criminated differences in HRQOL among populations
with HIV [15–19], the SHAS questionnaire's shorter 24-
item subset of the MOS questions may limit direct
comparison of our results with those of other studies. Still,
our findings from the HRQOL analysis in SHAS generally
agree with those in other published research.
Quality of life issues are also important for persons with
HIV as they relate to medication adherence. Complex
medication regimens and side effects can affect both qual-
ity of life and adherence [29–32]. Resistant viral strains
Table 3: Adjusted health-related quality of life measures, stratified by CD4 count (N = 3772)
Disability Measure CD4 <200 (n = 1950) (reference) CD4 200–499 (n = 812) CD4 ≥ 500 (n = 259) CD4 Unknown (n = 751)
mean 95% CL mean 95% CL mean 95% CL mean 95% CL
Overall Health 45.5 42.7–48.2 56.8a 53.7–59.9 64.7b,c 60.3–69.0 49.4 46.2–52.7
Pain 61.8 58.6–65.0 67.6 64.0–71.2 71.6c 66.6–76.6 64.8 61.0–68.5
Physical Functioning 56.6 53.4–59.7 70.7a 67.2–74.2 78.1c 73.2–83.1 67.0 63.3–70.7
Role Functioning 41.3 37.0–45.6 61.9a 57.0–66.7 74.9b,c 68.0–81.7 58.3 53.2–63.4
Social Functioning 61.8 58.7–64.9 75.3a 71.8–78.8 84.3b,c 79.4–89.1 70.5 66.9–74.2
Mental Health 57.1 54.8–59.3 59.1 56.5–61.6 61.1 57.5–64.6 58.7 56.0–61.3
Energy/Fatigue 45.4 43.0–47.7 53.3a 50.6–55.9 58.8c 55.0–62.5 49.8 47.0–52.6
Cognitive Functioning 71.0 68.6–73.4 74.2 71.5–76.9 76.4 72.7–80.2 78.0 75.2–80.8
least-squares means analysis; Tukey-Kramer adjustment for multiple comparisons; significance level P<0.05;
 * includes 318 persons who never had a CD4 test
 a significant pairwise difference: CD4 < 200 vs. CD4 200–499;
 b significant pairwise difference: CD4 200–499 vs. CD4 ≥ 500;
 c significant pairwise difference: CD4 < 200 vs. CD4 ≥ 500;
 CL= confidence limit
factors in model: age, education, sex, race/ethnicity, HIV risk, health insurance status, income time known HIV+, current antiretroviral status, type 
of recruitmentHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/12
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may emerge when adherence to antiretroviral regimens is
suboptimal. After the initial HRQOL module was used,
the SHAS questionnaire was modified to include ques-
tions on use of past and current medications (including
protease inhibitors), duration of current therapies, meas-
ures of adherence, and reasons for lack of adherence.
These questions should provide valuable new data on the
relationship of disease progression, therapy, and HRQOL
among participants in the SHAS Project.
Conclusions
The evolution toward treatment of HIV disease as a chron-
ic illness presents additional challenges for patients and
clinicians. Measures of health-related quality of life can
provide important information to behavioral and clinical
studies of antiretroviral treatment, adherence, and viral re-
sistance – factors that ultimately influence HIV-related
morbidity and mortality.
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